Key facts
- It has raised $4.0M across 1 recorded rounds; the latest was Seed Round ($1.8M) in May 2022.
- Notable investors include Endless Frontier Labs, Cambridge Scientific Products, Cobro Ventures, LabCentral, Minnow Venture Partners — 6 tracked in total.
- Vivtex has filed 1 Form D with the SEC, most recently Aug 2022 ($1.8M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Vivtex
Funding rounds
1 roundsAbout Vivtex
Operator of a novel healthcare platform intended for drug development using robotic technology. The company's platform enables the use of intact gastrointestinal tract tissue for fully automated robotic testing, enabling healthcare providers to treat patients with increased efficacy, safety, and adherence to existing and novel therapies.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2018
- Employees
- 17
- Website
- vivtex.com/
- Ownership
- Privately Held (backing)
Vivtex doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivtex shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivtex in its N-PORT filings yet. We sweep new filings monthly.